中国循证心血管医学杂志
中國循證心血管醫學雜誌
중국순증심혈관의학잡지
CHINESE JOURNAL OF EVIDENCE-BASES CARDIOVASCULAR MEDICINE
2014年
3期
271-273
,共3页
吴辉%杨俊%丁家望%李松%杨简%董武松%童晓红%李秀娟%李莉%吕志阳%张炯
吳輝%楊俊%丁傢望%李鬆%楊簡%董武鬆%童曉紅%李秀娟%李莉%呂誌暘%張炯
오휘%양준%정가망%리송%양간%동무송%동효홍%리수연%리리%려지양%장형
芪苈强心胶囊%扩张型心肌病%心功能%高迁移率族蛋白B1
芪藶彊心膠囊%擴張型心肌病%心功能%高遷移率族蛋白B1
기력강심효낭%확장형심기병%심공능%고천이솔족단백B1
Qili Qiangxin Capsules%Dilated cardiomyopathy%Heart function%High mobility group box 1 protein
目的:观察芪苈强心胶囊对扩张型心肌病患者心功能及高迁移率族蛋白B1(HMGB1)表达的影响。方法连续入选2012年1月~2013年8月在宜昌市中心人民医院心内科住院心功能(NYHA分级)Ⅱ~Ⅲ级的扩张型心肌病患者48例,随机分为观察组和对照组(各24例),两组患者均给予规范的西药治疗,观察组在此基础上加用芪苈强心胶囊(0.3 g/粒),每次4粒,3/日,疗程12周。分别测量两组患者治疗前后的6分钟步行距离(6MWT)及左室射血分数(LVEF);采用ELISA法检测两组患者血清中HMGB1、白细胞介素6(IL-6)及肿瘤坏死因子-α(TNF-α)的表达水平。结果与治疗前比较,治疗后两组患者6MWT、LVEF均显著提高(P<0.01),血清中HMGB1、IL-6及TNF-α的表达水平明显降低(P<0.01)。对照组治疗后6MWT为(365±59)m,LVEF为(39.3±8.8)%,与对照组比较,观察组治疗后6MWT[(389±63)m]、 LVEF [(44.6±9.3)%]显著升高(P<0.05)。对照组治疗后,血清中HMGB1、IL-6及TNF-α的水平分别为(13.37±3.86)pg/ml,(89.1±18.5)ng/ml,(18.3±4.2) ng/ml。与对照组治疗后比较,观察组治疗后血清中HMGB1[(9.61±3.25)pg/ml]、IL-6[(65.9±12.4) ng/ml]及TNF-α[(13.6±3.5)ng/ml]的表达水平降低(P<0.05)。结论芪苈强心胶囊辅助治疗能进一步改善扩张型心肌病患者的心功能,同时降低HMGB1及IL-6、TNF-α的表达。
目的:觀察芪藶彊心膠囊對擴張型心肌病患者心功能及高遷移率族蛋白B1(HMGB1)錶達的影響。方法連續入選2012年1月~2013年8月在宜昌市中心人民醫院心內科住院心功能(NYHA分級)Ⅱ~Ⅲ級的擴張型心肌病患者48例,隨機分為觀察組和對照組(各24例),兩組患者均給予規範的西藥治療,觀察組在此基礎上加用芪藶彊心膠囊(0.3 g/粒),每次4粒,3/日,療程12週。分彆測量兩組患者治療前後的6分鐘步行距離(6MWT)及左室射血分數(LVEF);採用ELISA法檢測兩組患者血清中HMGB1、白細胞介素6(IL-6)及腫瘤壞死因子-α(TNF-α)的錶達水平。結果與治療前比較,治療後兩組患者6MWT、LVEF均顯著提高(P<0.01),血清中HMGB1、IL-6及TNF-α的錶達水平明顯降低(P<0.01)。對照組治療後6MWT為(365±59)m,LVEF為(39.3±8.8)%,與對照組比較,觀察組治療後6MWT[(389±63)m]、 LVEF [(44.6±9.3)%]顯著升高(P<0.05)。對照組治療後,血清中HMGB1、IL-6及TNF-α的水平分彆為(13.37±3.86)pg/ml,(89.1±18.5)ng/ml,(18.3±4.2) ng/ml。與對照組治療後比較,觀察組治療後血清中HMGB1[(9.61±3.25)pg/ml]、IL-6[(65.9±12.4) ng/ml]及TNF-α[(13.6±3.5)ng/ml]的錶達水平降低(P<0.05)。結論芪藶彊心膠囊輔助治療能進一步改善擴張型心肌病患者的心功能,同時降低HMGB1及IL-6、TNF-α的錶達。
목적:관찰기력강심효낭대확장형심기병환자심공능급고천이솔족단백B1(HMGB1)표체적영향。방법련속입선2012년1월~2013년8월재의창시중심인민의원심내과주원심공능(NYHA분급)Ⅱ~Ⅲ급적확장형심기병환자48례,수궤분위관찰조화대조조(각24례),량조환자균급여규범적서약치료,관찰조재차기출상가용기력강심효낭(0.3 g/립),매차4립,3/일,료정12주。분별측량량조환자치료전후적6분종보행거리(6MWT)급좌실사혈분수(LVEF);채용ELISA법검측량조환자혈청중HMGB1、백세포개소6(IL-6)급종류배사인자-α(TNF-α)적표체수평。결과여치료전비교,치료후량조환자6MWT、LVEF균현저제고(P<0.01),혈청중HMGB1、IL-6급TNF-α적표체수평명현강저(P<0.01)。대조조치료후6MWT위(365±59)m,LVEF위(39.3±8.8)%,여대조조비교,관찰조치료후6MWT[(389±63)m]、 LVEF [(44.6±9.3)%]현저승고(P<0.05)。대조조치료후,혈청중HMGB1、IL-6급TNF-α적수평분별위(13.37±3.86)pg/ml,(89.1±18.5)ng/ml,(18.3±4.2) ng/ml。여대조조치료후비교,관찰조치료후혈청중HMGB1[(9.61±3.25)pg/ml]、IL-6[(65.9±12.4) ng/ml]급TNF-α[(13.6±3.5)ng/ml]적표체수평강저(P<0.05)。결론기력강심효낭보조치료능진일보개선확장형심기병환자적심공능,동시강저HMGB1급IL-6、TNF-α적표체。
Objective To observe the influences of Qili Qiangxin Capsules on heart function and expression of high mobility group box 1 protein (HMGB1) in the patients with dilated cardiomyopathy (DCM). Methods The patients (n=48) with grade II DCM and grade III DCM (NYHAgrading) were chosen from Jan. 2012 to Aug. 2013, and then divided randomly into observation group and control group (each n=24). Both groups were given standardized therapy of Western drugs and observation group was additionally given Qili Qiangxin Capsules (0.3 g/capsule) 4 capsules once and 3 times a day for 12 w. The changes of 6-minute walk test (6MWT) and LVEF were detected in 2 groups before and after treatment. The expressions of serum HMGB1, IL-6 and TNF-αwere detected by using ELISA. Results 6MWT and LVEF were increased significantly (P<0.01), and expressions of serum HMGB1, IL-6 and TNF-αdecreased significantly (P<0.01) in 2 groups after treatment. 6MWT was (365 ±59) m and LVEF was (39.3±8.8)%in control group, and 6MWT was [(389±63) m] and LVEF was [(44.6± 9.3)%] in observation group after treatment (P<0.05). The expressions of serum HMGB1, IL-6 and TNF-αwere, respectively, (13.37±3.86) pg/ml, (89.1±18.5) ng/ml and (18.3±4.2) ng/ml in control group, and[(9.61±3.25) pg/ml], [(65.9±12.4) ng/ml] and [(13.6±3.5) ng/ml] in observation group after treatment (P<0.05). Conclusion Qili Qiangxin Capsules can further improve heart function and reduce the expressions of HMGB1, IL-6 and TNF-αduring treatment in the patients with DCM.